154 related articles for article (PubMed ID: 10163967)
1. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer.
Hutton J; Brown R; Borowitz M; Abrams K; Rothman M; Shakespeare A
Pharmacoeconomics; 1996; 9 Suppl 2():8-22. PubMed ID: 10163967
[TBL] [Abstract][Full Text] [Related]
2. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Benedict A; Cameron DA; Corson H; Jones SE
Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Frías C; Cortés J; Seguí MÁ; Oyagüez I; Casado MÁ
Clin Transl Oncol; 2010 Oct; 12(10):692-700. PubMed ID: 20947484
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Brown RE; Hutton J
Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
[TBL] [Abstract][Full Text] [Related]
7. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Launois RJ; Reboul-Marty JM; Bonneterre J
Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of taxane therapy.
Yee GC
Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S11-5. PubMed ID: 9435927
[TBL] [Abstract][Full Text] [Related]
9. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Launois R; Reboul-Marty J; Henry B; Bonneterre J
Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
12. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
Hillner BE; Smith TJ; Desch CE
JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
17. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
Leung HWC; Chan ALF; Muo CH; Leung JH
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):207-213. PubMed ID: 28965422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
